AbbVie Inc. (ABBV)
|Net Income (ttm)||12.64B|
|Ex-Dividend Date||Jul 14, 2022|
|Day's Range||140.27 - 143.02|
|52-Week Range||105.56 - 175.91|
|Price Target||165.90 (+16.3%)|
|Earnings Date||Jul 29, 2022|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with ... [Read more...]
In 2021, AbbVie's revenue was $56.20 billion, an increase of 22.69% compared to the previous year's $45.80 billion. Earnings were $11.54 billion, an increase of 150.04%.Financial Statements
According to 31 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is 165.9, which is an increase of 16.34% from the latest price.
How the Inflation Reduction Act will affect Medicare
Yahoo Finance's Anjalee Khemlani breaks down the impacts the Inflation Reduction Act could have on Medicare enrollees should Congress pass it.
When the market is falling, this trio keeps rising.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
It won't be able to rely on Humira for growth for much longer.
AbbVie stock (NYSE: ABBV) reported its Q2 results last week, with revenue falling short and earnings above the street estimates.
JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION IRVINE, Calif. , Aug. 3, 2022 /PRNewswire/ -- Today, Allergan Aestheti...
Big pharma executives are worried that one part of the Inflation Reduction Act will reduce their companies' profits.
AbbVie has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $30.38B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 4.02% yield
Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines...
TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical compan...
With the market down close to 20% this year, passive income has become more important.
These stocks share several things in common.
ABBVIE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate ...
NEW ORLEANS , July 29, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
The drugmaker's Q2 results aren't sitting well with shareholders today.
AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales.
AbbVie (NYSE: ABBV ) recently published the company's second-quarter 2022 financial data. The results weren't very different from what Wall Street's analysts had expected.
AbbVie (ABBV) delivered earnings and revenue surprises of 1.81% and 0.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AbbVie narrowly topped second-quarter expectations Friday and reaffirmed its earnings outlook. But AbbVie stock fell early.
Shares of AbbVie Inc. ABBV, -0.93% were down 1.3% in premarket trading on Friday though the company met earnings and revenue expectations for the second quarter of the year. AbbVie had earnings of $924 ...
AbbVie Inc has set aside about $2 billion to resolve thousands of lawsuits against its Allergan unit over the marketing of its opioid products, the company said on Friday.
Reports Second-Quarter Diluted EPS of $0.51 on a GAAP Basis, an Increase of 21.4 Percent; Adjusted Diluted EPS of $3.37, an Increase of 11.2 Percent; These Results Include an Unfavorable Impact of $0.14...